InnoCan Pharma Corporation
INNPF
$0.14
$0.0086.06%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.38% | 111.22% | 176.96% | 333.85% | 331.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.38% | 111.22% | 176.96% | 333.85% | 331.10% |
| Cost of Revenue | 64.24% | 101.67% | 38.92% | 303.68% | 1,676.47% |
| Gross Profit | 2.80% | 112.31% | 201.13% | 338.03% | 289.55% |
| SG&A Expenses | 6.97% | 58.82% | 148.36% | 234.10% | 117.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.21% | 56.40% | 128.06% | 182.38% | 127.48% |
| Operating Income | -2.80% | 129.19% | 222.02% | 4.27% | 36.55% |
| Income Before Tax | 100.52% | 138.42% | 462.12% | 0.65% | 50.21% |
| Income Tax Expenses | -76.17% | -- | -- | -- | 21,300.00% |
| Earnings from Continuing Operations | 93.97% | 115.54% | 341.41% | -18.40% | 31.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 24.14% | -187.00% | -399.19% | -645.24% | -135.14% |
| Net Income | 87.09% | 85.69% | 164.81% | -39.13% | 26.84% |
| EBIT | -2.80% | 129.19% | 222.02% | 4.27% | 36.55% |
| EBITDA | -3.05% | 130.16% | 226.93% | 4.53% | 36.53% |
| EPS Basic | 87.88% | 87.18% | 157.14% | -27.45% | 31.25% |
| Normalized Basic EPS | 88.24% | 90.38% | 166.67% | -25.00% | 45.16% |
| EPS Diluted | 87.88% | 87.18% | 147.62% | -27.45% | 31.25% |
| Normalized Diluted EPS | 88.24% | 90.38% | 166.67% | -25.00% | 45.16% |
| Average Basic Shares Outstanding | 7.47% | 9.04% | 11.43% | 7.61% | 6.97% |
| Average Diluted Shares Outstanding | 7.47% | 9.04% | 11.43% | 7.61% | 6.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |